Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of
patients with mastocytosis with handicap and bearing activating point mutations in the
phosphotransferase domain of c-Kit such as the main mutation Asp-816-Val (D816V).